Skip to main content
Erschienen in: Journal of Gastroenterology 10/2013

01.10.2013 | Original Article—Alimentary Tract

Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America

verfasst von: Edyta Sutkowska, Robert D. McBane, Alfonso J. Tafur, Krzysztof Sutkowski, Diane E. Grill, Joshua P. Slusser, Waldemar E. Wysokinski

Erschienen in: Journal of Gastroenterology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The utility of thrombophilia testing in patients with splanchnic vein thrombosis (SpVT) has not previously been rigorously evaluated. The purpose of this study was to characterize differences in the prevalence of thrombophilia in patients with SpVT involving portal (PVT), mesenteric (MVT), splenic (SVT), or hepatic (HVT) veins in isolation or with multisegmental (M-SpVT) involvement compared to patients with lower extremity deep vein thrombosis (DVT).

Methods

An inception cohort of patients with incident SpVT was identified for whom comprehensive thrombophilia testing was performed between 1995 and 2005 and compared to DVT controls.

Results

341 patients with SpVT (mean age 50 ± 16 years, 53 % women) including isolated PVT (n = 112), MVT (n = 67), HVT (n = 22), SVT (n = 11), and M-SpVT (n = 129) involvement and 3621 DVT controls (mean age 55 ± 16 years, 56 % women) had comprehensive thrombophilia testing. The prevalence of abnormal results was similar for SpVT (24.6 %) and DVT (25.9 %) patients. “Strong” thrombophilias were more prevalent among SpVT patients (12.3 vs. 8.5 %, p = 0.0168). Patients with splenic (45.5 %) and mesenteric (41.8 %) thrombosis had the highest thrombophilia prevalence. Protein S deficiency was more common in SpVT patients (3.5 vs. 0.9 %, p < 0.001). In contrast, FV Leiden was more prevalent among DVT patients (15.8 vs. 10.9 %, p = 0.0497).

Conclusion

The prevalence of selected thrombophilia factors differ comparing SpVT and DVT patients. The prevalence is particularly high for patients with splenic and mesenteric vein thrombosis. Whereby the finding of strong thrombophilia impacts duration of anticoagulant therapy, such testing is warranted in the evaluation of patients with unprovoked SpVT.
Literatur
1.
Zurück zum Zitat McBane RD, Wysokinski WE. Treatment of venous thrombosis at unusual sites. Curr Treat Options Cardiovasc Med. 2008;10(2):136–45.PubMedCrossRef McBane RD, Wysokinski WE. Treatment of venous thrombosis at unusual sites. Curr Treat Options Cardiovasc Med. 2008;10(2):136–45.PubMedCrossRef
2.
Zurück zum Zitat Thatipelli MR, McBane RD, Hodge DO, et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200–5.PubMedCrossRef Thatipelli MR, McBane RD, Hodge DO, et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200–5.PubMedCrossRef
3.
Zurück zum Zitat Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51(1):210–8.PubMedCrossRef Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51(1):210–8.PubMedCrossRef
4.
Zurück zum Zitat Mushlin PS, Gelman S. Hepatic physiology and pathophysiology. In: Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL, editors. Miller's Anesthesia, 7th ed. Churchill Livingstone, an Imprint of Elsevier; 2009. p. 411–20. Mushlin PS, Gelman S. Hepatic physiology and pathophysiology. In: Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL, editors. Miller's Anesthesia, 7th ed. Churchill Livingstone, an Imprint of Elsevier; 2009. p. 411–20.
5.
Zurück zum Zitat Shetty S, Ghosh K. Thrombophilic dimension of Budd Chiari syndrome and portal venous thrombosis—a concise review. Thromb Res. 2011;127(6):505–12.PubMedCrossRef Shetty S, Ghosh K. Thrombophilic dimension of Budd Chiari syndrome and portal venous thrombosis—a concise review. Thromb Res. 2011;127(6):505–12.PubMedCrossRef
6.
Zurück zum Zitat Pinto RB, Silveira TR, Bandinelli E, et al. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. J Pediatr Surg. 2004;39(9):1356–61.PubMedCrossRef Pinto RB, Silveira TR, Bandinelli E, et al. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. J Pediatr Surg. 2004;39(9):1356–61.PubMedCrossRef
7.
Zurück zum Zitat Dentali F, Galli M, Gianni M, et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A meta-analysis. Thromb Haemost. 2008;99(4):675–82.PubMed Dentali F, Galli M, Gianni M, et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A meta-analysis. Thromb Haemost. 2008;99(4):675–82.PubMed
8.
Zurück zum Zitat Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96(7):2364–8.PubMed Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96(7):2364–8.PubMed
9.
Zurück zum Zitat Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd–Chiari syndrome. Gut. 2001;48(2):264–8.PubMedCrossRef Deltenre P, Denninger MH, Hillaire S, et al. Factor V Leiden related Budd–Chiari syndrome. Gut. 2001;48(2):264–8.PubMedCrossRef
10.
Zurück zum Zitat Smalberg JH, Kruip MJ, Janssen HL, et al. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol. 2011;31(3):485–93.PubMedCrossRef Smalberg JH, Kruip MJ, Janssen HL, et al. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol. 2011;31(3):485–93.PubMedCrossRef
11.
Zurück zum Zitat De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med. 2010;5(6):487–94.PubMedCrossRef De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med. 2010;5(6):487–94.PubMedCrossRef
12.
Zurück zum Zitat Rajani R, Melin T. Björnsson et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival—an 18-year experience. Liver Int. 2009;29(2):253–9.PubMedCrossRef Rajani R, Melin T. Björnsson et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival—an 18-year experience. Liver Int. 2009;29(2):253–9.PubMedCrossRef
13.
Zurück zum Zitat Mahmoud AE, Elias E, Beauchamp N, et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut. 1997;40(6):798–800.PubMedCrossRef Mahmoud AE, Elias E, Beauchamp N, et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut. 1997;40(6):798–800.PubMedCrossRef
14.
Zurück zum Zitat Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31(2):345–8.PubMedCrossRef Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31(2):345–8.PubMedCrossRef
15.
Zurück zum Zitat Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41(3):603–8.PubMedCrossRef Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41(3):603–8.PubMedCrossRef
16.
Zurück zum Zitat Murad DS, Plessier A, Hernandez-Guerra M et al. Etiology, management, and outcome of the Budd–Chiari syndrome. Ann Intern Med. 2009; 151(3):167–75. Murad DS, Plessier A, Hernandez-Guerra M et al. Etiology, management, and outcome of the Budd–Chiari syndrome. Ann Intern Med. 2009; 151(3):167–75.
17.
Zurück zum Zitat Francis RB, Seyfert U. Rapid amidolytic assay for protein C in whole plasma using an activator from the venom of agkistrodon contortrix. Am J Clin Pathol. 1987;87:619–25.PubMed Francis RB, Seyfert U. Rapid amidolytic assay for protein C in whole plasma using an activator from the venom of agkistrodon contortrix. Am J Clin Pathol. 1987;87:619–25.PubMed
18.
Zurück zum Zitat Laroche P, Plassart V, Amiral J. Rapid quantitative latex immunoassays for diagnosis of thrombotic disorders. Thromb Haemost. 1989;62:379. Laroche P, Plassart V, Amiral J. Rapid quantitative latex immunoassays for diagnosis of thrombotic disorders. Thromb Haemost. 1989;62:379.
19.
Zurück zum Zitat Zöller B. García de Frutos P, Dahlbäck B. Evaluation of the relation between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 1995;85:3524–31.PubMed Zöller B. García de Frutos P, Dahlbäck B. Evaluation of the relation between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 1995;85:3524–31.PubMed
20.
Zurück zum Zitat Tollefsen DM. Laboratory Diagnosis of Antithrombin and Heparin Cofactor II Deficiency. Sem Thromb Haemost. 1990;16:162–8.CrossRef Tollefsen DM. Laboratory Diagnosis of Antithrombin and Heparin Cofactor II Deficiency. Sem Thromb Haemost. 1990;16:162–8.CrossRef
21.
Zurück zum Zitat Kapiotis S, Quehenberger P, Jilma B, et al. Improved characteristics of APC resistance assay, coatest aPC resistance by predilution of samples with Factor V deficient plasma. Am J Clin Pathol. 1996;106:588–93.PubMed Kapiotis S, Quehenberger P, Jilma B, et al. Improved characteristics of APC resistance assay, coatest aPC resistance by predilution of samples with Factor V deficient plasma. Am J Clin Pathol. 1996;106:588–93.PubMed
22.
Zurück zum Zitat Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated Protein C. Nature. 1994;369:64–7.PubMedCrossRef Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated Protein C. Nature. 1994;369:64–7.PubMedCrossRef
23.
Zurück zum Zitat Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.PubMed Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.PubMed
24.
Zurück zum Zitat Proven A, Bartlett RP, Moder KG, et al. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc. 2004;79(4):467–75.PubMedCrossRef Proven A, Bartlett RP, Moder KG, et al. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc. 2004;79(4):467–75.PubMedCrossRef
25.
Zurück zum Zitat Magera MJ, Lacey JM, Casetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem. 1999;45(9):1517–22.PubMed Magera MJ, Lacey JM, Casetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem. 1999;45(9):1517–22.PubMed
26.
Zurück zum Zitat Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med. 2009;11(2):114–28.PubMedCrossRef Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med. 2009;11(2):114–28.PubMedCrossRef
27.
Zurück zum Zitat SAS Institute Inc. SAS®/STAT User’s Guide, version 9 ed. Cary: SAS Institute Inc.; 2005. SAS Institute Inc. SAS®/STAT User’s Guide, version 9 ed. Cary: SAS Institute Inc.; 2005.
28.
Zurück zum Zitat Marchiori A, Mosena L, Prins MH, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica. 2007;92(8):1107–14.PubMedCrossRef Marchiori A, Mosena L, Prins MH, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica. 2007;92(8):1107–14.PubMedCrossRef
29.
Zurück zum Zitat Schwarz HP. Extra-hepatic synthesis of protein S. Thromb Haemost. 1990;64(2):333–4.PubMed Schwarz HP. Extra-hepatic synthesis of protein S. Thromb Haemost. 1990;64(2):333–4.PubMed
30.
Zurück zum Zitat Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31(3):587–91.PubMedCrossRef Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31(3):587–91.PubMedCrossRef
31.
Zurück zum Zitat Violi F, Ferro D, Basili S, et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ. 1994;309(6949):239–40.PubMedCrossRef Violi F, Ferro D, Basili S, et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ. 1994;309(6949):239–40.PubMedCrossRef
32.
Zurück zum Zitat Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130(7):2031–8.PubMedCrossRef Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130(7):2031–8.PubMedCrossRef
Metadaten
Titel
Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America
verfasst von
Edyta Sutkowska
Robert D. McBane
Alfonso J. Tafur
Krzysztof Sutkowski
Diane E. Grill
Joshua P. Slusser
Waldemar E. Wysokinski
Publikationsdatum
01.10.2013
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 10/2013
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0728-3

Weitere Artikel der Ausgabe 10/2013

Journal of Gastroenterology 10/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.